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ABSTRACT 
Objective: Experiments were performed to design, develop and characterize bilayer buoyant tablets having tramadol (TH), immediate release (IR) 
layer and gabapentin (GBP), sustained release (SR) layer.  
Methods: Natural hydrophilic polysaccharide disintegrants were modified by sequential processes to obtain treated xanthan gum (TXG) and 
treated gellan gum (TGG), utilized for IR layer whereas carbopol and sodium carboxymethylcellulose, as sustaining polymers for SR layer and gas 
producing substance sodium bicarbonate which librates carbon dioxide for adequate buoyancy, was used in formulated bilayer tablet. A full two-
level factorial experimental design was used for sustaining GBP release from buoyant SR layer.  
Results: Fourier transform infrared spectroscopy (FT-IR) and differential scanning calorimetry (DSC) studies conducted, explain overall drug and 
excipients compatibility. More than 90% of tramadol was released from IR layer within 30 min. Diffusion exponents (0.36-0.59) and T50% (2.4-4.4h) 
were determined for all SR tablet formulations. Optimised (S7) formulation exhibited 95.77% GBP released over 12h.  
Conclusion: Developed tablet can provide excellent therapeutic result by the sequential immediate release of TH and sustained release of GBP for 
effective combination pharmacotherapy of neuropathic pain with once a day administration. 
Keywords: Bilayer tablet, Tramadol, Neuropathic pain, Gabapentin, GBDDS 




Neuropathy a disease of the nerve is the common cause of pain in the 
modern world. Chronic neuropathic pain is the most disturbing 
symptom of lesions in the peripheral nervous system that can be of 
many forms. Peripheral neuropathy is often distressing may produce 
disabilities or even found to be fatal. There are several things that 
cause neuropathies, patients with conditions as diverse as diabetes-
induced neuropathy, human immunodeficiency virus (HIV) sensory 
neuropathy, post-stroke syndromes, and multiple sclerosis frequently 
experience daily pain that greatly impairs their quality of life [1, 2]. 
Tramadol hydrochloride (TH), (±) cis-2-[(dimethylamino) methyl]-
1-(3-methoxyphenyl) cyclohexanol hydrochloride a synthetic opioid 
analgesic acts centrally, binds with the μ-opioid receptors, produce 
week suppression of norepinephrine and serotonin re-acceptance. 
This mechanism may unconventionally assist for pain relief along 
with overall analgesic effect [3]. 
Gabapentin (GBP), 2-[1-(aminomethyl)cyclohexyl] acetic acid is a 
synthetic analogue of the neurotransmitter gamma-aminobutyric acid 
has no activity at GABA A or GABA B receptors but its modulation of 
GABA synthesis and glutamate synthesis activity were considered very 
important for its pharmacological action. It interacts with a high-affinity 
binding site in nerve cell membranes, bind to the alpha-2-delta subunit 
of voltage gated calcium ion channels resulting in reduced depolarisation 
effected calcium flow in the nerve terminals which causes the decline of 
excitatory neurotransmitters release. In addition to epilepsy, GBP has 
demonstrated excellent efficacy for the treatment of neuropathic pain 
and often considered as choice of drug in first-line treatments for various 
neuropathic pain syndromes, generally irrespective of cause [4, 5]. 
Chronic neuropathic pain is a disease, not a symptom and 
combination pharmacotherapy is often necessary. A major goal of 
neuropathic pain management is to provide pain relief that is 
clinically meaningful, sustained, and associated with the minimum 
and reversible adverse effects. Efficacy of single agents for chronic 
neuropathic pain is limited; there is a need either to develop new 
and more effective drugs or to identify favourable combinations of 
drugs that are already available. Oral combination drug delivery 
systems have been proven to be highly beneficial and essential in the 
treatment of neuropathic pain [6]. In recent years, gastroretentive 
peroral drug delivery systems have attracted more and more 
attention, the gastric buoyant drug delivery system GBDDS is able to 
stretch out the confinement of a dosage form in the stomach for a 
longer time, thereby increasing therapeutic effectiveness of the API 
through improving the pharmacokinetics of the drug [7, 8].  
The present work focuses on the development and characterization 
of bilayer tablet of tramadol (TH) 50 mg, immediate release and 
gabapentin (GBP) 100 mg, sustained release for effective around-
the-clock treatment of neuropathic pain. Optimization of GBDDS, 23 
factorial design was employed; formulation control variables, 
carbopol 934; carbopol 940 two viscosity grades, polymer-to-
polymer proportion and total polymer content-to-drug content 
proportion were examined. The study includes total buoyancy time 
(TBT), quantity (%) of GBP release at 12 h, the time required to 
remain half (T50%) and exponent of diffusion (n) as a dependent 
variable. Detail regression analysis was made to achieve best 
possible composition for tablet formulation [9]. 
MATERIALS AND METHODS 
Materials 
TH and GBP was a gift from Wockhardt Pvt. Ltd. (Aurangabad, India). 
carbopol 934; carbopol 940, was supplied by Colorcon Asia Pvt. Ltd. 
(Goa, India); xanthan gum (XG), gellan gum (GG), sodium 
carboxymethylcellulose, microcrystalline cellulose, tartrazine, sodium 
bicarbonate, lactose, dicalcium phosphate, the talc-pharmaceutical 
grade was purchased from local authorized dealers. All other reagents 
and chemicals used were of analytical reagent grade. 
Methods 
Drug-excipient interaction study 
One of the critical primary concerns for any dosage form is the 
compatibility of drug, polymer and other excipients; hence it is 
essential to assure that in investigational circumstances drug 
doesn’t have any interaction with excipients. Fourier transform 
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infrared spectroscopy (FT-IR) and differential scanning calorimetry 
(DSC) investigations were made to detect possible interaction. 
FT-IR spectral investigation 
Samples of pure drug TH, GBP, IR layer composition and SR layer 
composition were differently crushed with KBr to make pallets for 
the IR spectra using Shimadzu IR Affinity-1S FTIR spectro-
photometer (Shimadzu, Japan).  
DSC thermogram investigation  
The thermograms for TH, GBP, IR layer composition and SR layer 
composition were prepared by using (Perkin Elmer Cyris) DSC. 
Temperature and enthalpy scale of the DSC was calibrated using 
indium (In). Aluminium vessels were used to seal the sample under 
test and then heated over a temperature scale of 50-200 °C with an 
invariable pace of 10 °C/min [10]. 
Modification of disintegrants 
Natural hydrophilic polysaccharides were modified by sequential 
processes to obtain treated xanthan gum (TXG) and treated gellan 
gum (TGG). 10 gm powder of polysaccharide was mixed with 
sufficient distilled water and allowed to swell for 1 d. Then spread 
mechanically in a petri dish and allowed for drying up to 3 d in an 
incubator at 37±1 °C [11]. 
Immediate release TH tablet formulation 
TH immediate release blend was prepared in porcelain mortar; 
tramadol (TH), half of the quantity of disintegrant (TXG or TGG) 
and other excipients were mixed up to 15 min. Sufficient amount 
of water as a granulating liquid was added to produce wet mass 
which was then passed through 10# sieve for granulation and 
dried in an oven at 50 °C for 30 min. Dry granules were screened 
through 14# sieve; calculated quantity of 10% fines was 
incorporated and mixed in a poly bag with a remaining quantity 
of TXG or TGG, magnesium stearate and talc for 5 min. The TH-
granules were compressed on single punch tablet compression 
machine [CADMAC (CMS-SN H/432/96), Ahmedabad, India] 
using 8 mm round flat-faced punch. Various powder 
characteristics for TH-granules were investigated before 
compression (table 1) provides compositions for different 
experimental batches. 
 
Table 1: Composition of tramadol IR tablet 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
1 TH 50 50 50 50 50 50 50 50 
2 MCC 30 30 30 30 30 30 30 30 
3 TXG 3 6 12 18 - - - - 
4 TGG - - - - 3 6 12 18 
5 Tartarazine 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
6 Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
7 Magnesium stearate 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 
8 Dicalcium phosphate QS QS QS QS QS QS QS QS 
TH: Tramadol hydrochloride, MCC: Microcrystalline cellulose, TXG: Treated xanthan gum, TGG: Treated gellan gum, Values represented in mg. Total 
weight 150 mg per tablet. 
 
Precompression parameters-evaluation of TH blend 
The TH-granules of all batches were characterized as per disclosed 
approaches for density (loose bulk density and tapped bulk density), 
the angle of repose, Hausner’s ratio and compressibility index [12]. 
Evaluation of immediate release TH tablet 
As per standard methods, all batches of TH-tablet were 
characterized for appearance, thickness, weight variation, hardness 
and friability [13]. 
Drug content 
Twenty tablets were weighed, powdered and 50 mg equivalent 
weight of TH was accurately weighed, transferred into a 100 ml 
volumetric flask and dissolved in phosphate buffer pH 7.4 with 
sonication for 10 min, volume was made up to the mark. The 
solution in the volumetric flask was filtered; suitable dilutions were 
made and analyzed at 273 nm on UV-visible spectrophotometer 
(Shimadzu UV-1601). Maximum absorbance (λmax) for TH was 
determined UV-spectrophotometrically by scanning dilute TH 
solution in phosphate buffer pH 7.4 at 200 nm to 400 nm. The drug 
content of each sample was estimated using standard calibration 
curve of TH in phosphate pH 7.4 buffer [14]. 
Disintegration study 
Disintegration test was performed on arbitrarily selected six tablets 
from each batch. The tablets were placed without a disc in United 
States Pharmacopeia (USP) disintegration test apparatus filled with 
simulated gastric fluid and temperature was maintained at 37±0.5 °C. 
Disintegration time for six tablets was expressed as mean±standard 
deviation (SD) [15]. 
Dissolution study 
Dissolution test of TH tablet was performed in the simulated gastric 
fluid as dissolution medium (900 ml) using USP dissolution test 
apparatus-II (LABINDIA DS8000+) at 50 rpm and 37±0.5 °C 
temperature. A test sample (5 ml) was withdrawn at specific time 
intervals (1, 3, 5, 10, 15, 20 and 30 min) and replaced with fresh 
dissolution media maintained at 37±0.5 °C. The test sample was 
filtered (membrane filter, 0.45 μm) and the concentration of 
dissolved drug was determined using ultraviolet (UV) 
spectrophotometer at λ max 273 nm. This test was performed on six 
tablets and mean±SD calculated. 
Buoyant sustained release GBP tablet formulation 
Experimental design 
A 2-level full-factorial design comprising of 8 full-factorial design 
points; according to the model, 8 experiments were conducted in 
total. This design involves independent or controlled variables 
polymer content-to-drug content proportion (X1), the polymer-to-
polymer proportion (X2) and polymer grade (X3) [carbopol 934 and 
carbopol 940]; the levels of independent variables are shown in 
(table 2). The dependent variables Y1, percentage of GBP release at 
12 h; Y2, T50%; Y3, diffusion exponent (n); and Y4, buoyancy time 
were investigated. 
 
Table 2: Level of variables for investigation 
Coded values Controlled variables 
Polymer: drug (X1) Polymer: polymer (X2) Grade of polymer (X3) 
-1 1:1 1:1 Carboplo 934 
1 2:1 3:1 Carboplo 940 
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Preparation of buoyant tablets 
Wet granulation approach was used for the preparation of buoyant 
sustained release granules. Required quantity of gabapentin (GBP), 
and polymers (carbopol 934 or carbopol 940 and sodium 
carboxymethylcellulose), gas generating agent (sodium 
bicarbonate), and acidifying agent (citric acid) was accurately 
weighed, passed through sieve #40 and were mixed homogeneously 
in a poly bag for about 10 min, transferred to a mortar. To the 
mortar 5% PVP K30 in isopropyl alcohol was as a granulating agent 
was added in sufficient quantity to produce the wet mass which was 
passed through sieve #10 and dried in hot air oven at 50 °C for 30 
min; dried granules were screened through sieve #14. Finally, 10% 
fine was added to granules and was lubricated in a poly bag with 
magnesium stearate and talc for 5 min. The GBP-granules were 
compressed on single punch tablet compression machine [CADMAC 
(CMS-SN H/432/96), Ahmedabad, India] using 10 mm round flat-
faced punch. Various powder characteristics for GBP-granules were 
investigated before compression. About 6-8 kg/cm2 tablet crushing 
strength, consistently maintained during compression and 100 
tablets per batch were prepared for all compositions; (table 3) 
provides compositions for different experimental batches. 
 
Table 3: Composition of gabapentin SR tablet 
S. No. Ingredients S1 S2 S3 S4 S5 S6 S7 S8 
1 GBP 100 100 100 100 100 100 100 100 
2 Carbopol 934 50 75 100 150 - - - - 
3 Carbopol 940 - - - - 50 75 100 150 
4 SCMC 50 25 100 50 50 25 100 50 
5 Sodium bicarbonate 85 85 85 85 85 85 85 85 
6 Citric acid 21.30 21.30 21.30 21.30 21.30 21.30 21.30 21.30 
7 Talc 04.25 04.25 04.25 04.25 04.25 04.25 04.25 04.25 
8 Magnesium stearate 02.13 02.13 02.13 02.13 02.13 02.13 02.13 02.13 
9 PVP K30 5% in IPA QS QS QS QS QS QS QS QS 
10 Dicalcium phosphate QS QS QS QS QS QS QS QS 
GBP: Gabapentin, SCMC: Sodium carboxymethylcellulose sodium, PVP K30: Polyvinylpyrrolidone K30, IPA: Isopropyl alcohol, Values represented in 
mg, Total weight 425 mg per tablet 
 
Precompression parameters-evaluation of GBP blend 
The GBP-granules of all batches were characterized as per disclosed 
approaches for density (loose bulk density and tapped bulk density), 
the angle of repose, Hausner’s ratio and compressibility index [12]. 
Evaluation of buoyant sustained release GBP tablet 
As per standard methods, all batches of GBP tablet were characterized 
for appearance, thickness, weight variation, hardness and friability [13]. 
BLT and TBT for GBP tablet 
Buoyancy lag time (BLT) is the time required for a tablet to float 
over the gastric fluid, the in vitro buoyancy in simulated conditions 
was determined by the floating lag time. Tablets were placed in a 
250 ml beaker containing 0.1N HCl maintained at 37 °C. The time 
required for the tablet to rise to the surface for floating was 
determined as the buoyancy lag time and further total buoyancy 
time (TBT) of all tablets was determined by visual observation [10]. 
Swelling studies  
The extent of swelling was measured in terms of % of weight gained 
by the tablet that may be used to predict drug release behaviour 
from the tablets. One tablet from each formulation was weighed and 
kept in a petri dish containing 50 ml of 0.1 N HCl solution. At the end 
of specified time intervals, tablets were withdrawn from a petri dish, 
excess buffer blotted with tissue paper and weighed. The % of 
weight gained (swelling index) was calculated by using following 
formula (Eq 1) [16]. 
Swelling index % = Wt − W0
W0
 × 100 … 1 
Where, Wt = Weight of tablet at time = t;  
W0 = Weight of tablet before immersion (time = 0) 
Drug content 
Twenty tablets were weighed, triturated to powder and 100 mg 
accurately weighed the equivalent weight of GBP was transferred 
into a 100 ml volumetric flask, dissolved in phosphate buffer pH 7.4 
with sonication for 10 min; volume was made up to the mark. The 
solution in the volumetric flask was filtered through 0.45 μm 
membrane filter and suitable dilutions were made and analyzed at 
212 nm on UV-Visible spectrophotometer (Shimadzu UV-1601). 
The drug content of each sample was estimated using standard 
calibration curve of GBP in phosphate buffer pH 7.4. During 
dissolution studies, GBP exhibited good absorption at 212 nm by 
using phosphate buffer pH 7.4 as a dissolution media. All results 
were represented as a mean±SD [17]. 
Dissolution study 
The in vitro dissolution studies were carried out in USP type II 
apparatus (LABINDIA DS8000+) at 50 rpm using simulated gastric 
fluid as dissolution medium (900 ml) maintained at 37±0.5 °C. Drug 
release at different time interval was measured by UV-visible 
spectrophotometer at 212 nm. The release studies were conducted 
on six tablets in each batch; results were represented as a mean±SD. 
Drug release kinetics 
In vitro GBP release data was used to establish release kinetics by 
constructing graphs for different kinetic models, like cumulative 
quantity of drug released vs time (Eq. 2) for zero order, log 
cumulative % drug remaining vs time (Eq. 3) for first order and 
cumulative percentage of drug released vs square root of time (Eq. 
4) for Higuchi’s release model. 
C = k0t … 2 
Where ‘k0’ is the zero order rate constant expressed in units of 
concentration/time and ‘t’ is the time in hours. A graph of 
concentration vs time would yield a straight line with a slope equal 
to ‘k0’ and intercept the origin of the axes. 
log C = log C0 − kt 2.303⁄  … 3 
Where ‘C0’ is the initial concentration of the drug, ‘k’ is the first order 




2  … 4 
Where ‘k’ is the constant reflecting the design variables of the 
system and ‘t’ is the time in hours. [18]. 
Curve fitting of the release profile  
To evaluate the mechanism of drug release from GBP sustained 
release tablet, the first 60% of cumulative drug release data were 
plotted in Korsmeyer et al.’s equation (Eq. 5) as log cumulative 
percentage of drug released vs log time, and the exponent n was 
calculated through the slope of the straight line. 
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 = ktn  … 5 
Within equation, a fraction of GBP released was Mt/M∞ at 
release time ‘t’, the distinctive drug-polymer system kinetic 
constant ‘k’ whereas the exponent ‘n’ specifies the drug release 
mechanism. Based on the values of ‘n’ from Korsmeyer-Peppas 
equation, circular cylinder shape matrix tablets can follow 
release mechanisms; quasi fickian diffusion for n<0.5; fickian 
diffusion for n=0.5; freakish diffusion for 0.5<n<1. The 
symbolic value n=1 provides case-II transport or classical zero 
order transport; non fickian super case II if n>1. The overall 
curve-fitting analysis was performed with the help of 
‘GraphPad Prism’ software version 3.06 and ‘Microsoft Excel’ 
software version MS Office 2007 [19]. 
Bilayer buoyant tablet of TH and GBP 
Development of bilayer buoyant tablets was carried in two different 
stages, blends of the immediate release layer of TH and sustained 
release buoyant layer of GBP were prepared separately and after 
optimization of an individual layer, the bilayer tablet was prepared 
using selected formulas. An optimized batch of TH (F3) and GBP (S7) 
was selected for the formulation of bilayer tablet and were 
compressed using 10 mm round flat faced punch of the single punch 
tablet compression machine [CADMAC (CMS-SN H/432/96), 
Ahmedabad India]. First, the granules of buoyant SR layer were 
poured in the die cavity and compressed with moderate force. Then 
the upper punch was lifted and the IR granules were poured in the 
die cavity, containing initially compressed SR layer and compressed 
with full force to form bilayer tablet with a hardness of 6-8 kg/cm2. 
The hardness was kept constant for all tablets and was measured 
using Monsanto hardness tester [20-25]. 
Evaluation for bilayer buoyant tablet of TH and GBP 
As per standard methods, bilayer tablets of TH and GBP were 
characterized for appearance, tablet thickness, weight variation, 
hardness, friability, BLT and TBT. Uniformity of content for two 
drugs TH and GBP was determined independently for each layer 
through splitting the powder of bilayer tablet. 
Dissolution study 
The in vitro dissolution studies were carried out in two phases 
using USP type II apparatus (LABINDIA DS8000+) at 50 rpm using 
the simulated gastric fluid as dissolution medium (900 ml) 
maintained at 37±0.5 °C. The drug release at different time 
intervals was measured by UV-visible spectrophotometer at 273 
nm and 212 nm for TH and GBP respectively.  
The release studies were conducted on six tablets, and the mean 
values were plotted versus time with SD. 
RESULTS AND DISCUSSION 
Drug-excipients interaction study 
Fourier transform infrared spectroscopy (FT-IR) investigation 
spectra for TH, GBP and the polymer mix was exhibited relevant 
characteristic prominent peaks for respective drugs showing no 
interaction indicated overall compatibility of drugs with the 
excipients. Differential scanning calorimetry (DSC) 
thermogrames for TH, GBP, IR layer composition, SR layer 
composition exhibited no interaction, the distinctive melting 
points observed for TH at 184 °C and for GBP at 175 °C and no 
evident melting point changes were noted indicating overall 
compatibility. 
Powder characterization  
Various powder attributes like density (LBD and TBD), angle of 
repose, Hausner’s ratio and compressibility index for all batches of 
IR blend containing TH and SR blend containing GBP (table 4) 
exhibited excellent characteristics. The angle of repose (26.80-
34.40) and Hausner’s ratio<1.13 for all batches indicated good flow 
properties.
 
Table 4: Precompression parameters 
 Tramadol IR blend Gabapentin SR blend 
Batch F1 F2 F3 F4 F5 F6 F7 F8 S1 S2 S3 S4 S5 S6 S7 S8 
AR 32.45 29.72 27.36 26.80 33.47 28.55 29.24 30.53 33.35 34.40 29.23 31.45 29.62 27.42 31.65 30.78 
LBD 0.72 0.74 0.60 0.58 0.56 0.57 0.61 0.55 0.48 0.52 0.55 0.53 0.50 0.48 0.52 0.49 
TBD 0.86 0.85 0.72 0.66 0.65 0.68 0.73 0.64 0.56 0.60 0.63 0.62 0.59 0.57 0.59 0.58 
CI (%) 16.27 12.79 16.66 12.12 13.84 16.17 16.43 14.06 14.28 13.33 12.69 14.51 15.25 15.78 11.86 15.51 
HR 1.19 1.14 1.20 1.13 1.16 1.19 1.20 1.16 1.16 1.15 1.14 1.17 1.18 1.18 1.13 1.18 
AR: Angle of repose, CI: Compressibility index, HR: Hausner’s ratio 
 
Evaluation of tablets 
All tablets appeared smooth flat circular; different characteristics 
like tablet thickness, tablet weight variation, crushing strengths 
(hardness), tablet friability, tablet disintegration time, drug content, 
BLT and TBT were represented for TH tablet formulations (table 5) 
and GBP tablet formulations (table 6). All tablet batches qualifies, 
tablet weight variation test as found variation 100±5 % within 
range; friability below 1%; drug content 90-110% within limit and 
deviation in thickness found less than 5%. 
 
Table 5: Evaluation parameters of TH tablet 
Batch Weight* (mg) Thickness* (mm) Hardness* (Kg/cm2) Friability# (%) Disintegration time* (Sec) Drug content* (%) 
F1 157.0±1.32 2.31 5.0±0.17 0.58 210±20.80 099.8±0.97 
F2 151.5±1.60 2.29 4.7±0.26 0.46 168±16.32 101.2±0.88 
F3 158.5±1.27 2.34 5.1±0.24 0.41 122±10.63 100.7±1.34 
F4 151.1±1.54 2.36 4.8±0.12 0.53 150±11.27 099.7±1.96 
F5 149.8±1.35 2.28 5.2±0.27 0.59 224±15.90 100.5±1.45 
F6 152.6±1.48 2.32 5.3±0.32 0.46 177±11.52 101.0±1.62 
F7 154.8±1.65 2.35 4.9±0.20 0.72 148±11.61 099.7±1.38 
F8 151.5±1.75 2.30 4.6±0.20 0.64 170±10.82 100.4±0.98 
*Readings expressed in mean±SD for three measurements, #Readings expressed for a single measurement 
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Table 6: Evaluation parameters of GBP tablet 
Batch Weight* 
(mg) 






S1 425.6±1.24 3.24 6.3±0.37 0.58 102.6±1.34 69 9.92 
S2 426.2±1.44 3.19 6.0±0.33 0.59 099.8±1.27 58 10.96 
S3 424.9±1.65 3.22 6.4±0.25 0.63 101.4±0.77 72 20.11 
S4 428.5±0.97 3.24 5.9±0.24 0.58 099.6±0.89 67 17.90 
S5 428.6±1.48 3.26 6.1±0.27 0.62 102.1±1.62 56 11.35 
S6 423.6±1.83 3.19 6.6±0.38 0.55 100.8±0.87 70 12.53 
S7 425.8±1.33 3.21 6.3±0.34 0.72 101.6±1.26 62 20.85 
S8 427.9±1.82 3.20 5.8±0.12 0.64 099.9±1.52 77 18.78 
BLT: Buoyancy lag time, TBT: Total buoyancy time, *Readings expressed in mean±SD for three measurements, #Readings expressed for single 
measurement 
 
Disintegration and dissolution study of TH tablet 
Hydrophilic polysaccharides XG and GG interact with aqueous 
solutions by three-dimensional swelling, to an equilibrium value and 
physically entrap a significant portion of water within their structure. 
Drying at this stage leads to evaporation of water leaving behind a 
porous structure. This structural modification of TXG and TGG does 
not allow the formation of gelatinous mass in water resulting in low 
water solubility and extensive swelling properties for faster 
disintegration. Disintegration efficiency of disintegrants like TXG and 
TGG was comparatively investigated. Wetting time for a tablet 
containing TXG was found minimum as compared to tablets containing 
TGG, the higher capability of absorbing water and swelling of TXG 
provides faster disintegration of batch F3 (122±10.63 s), consequently 
selected as best composition of TH layer to prepare bilayer tablet. 
Disintegration time for all batches was represented in (fig. 1).  
In vitro drug release at 1, 3, 5, 10, 15, 20 and 30 min for all batches was 
expressed by a graph cumulative % drug released vs time (fig. 2). The 
release of TH was depended on its concentration in the IR tablet 
formulation and therefore followed first-order release kinetics. 
 
Fig. 1: Disintegration time of TH immediate release tablet 
formulations (Results are expressed as mean±SD, n=3)
 
 
Fig. 2: In vitro drug release profile of TH immediate release tablet formulations (Results are expressed as mean±SD, n=6) 
 
Dissolution study of GBP tablet 
GBP is absorbed in the small intestine by diffusion and facilitated 
transport, this carrier dependent saturable transport is the reason 
for its invariable bioavailability. If GBP is presented through 
sustained release gastro retentive dosage form its effectiveness in 
neuropathic pain management can be increased many folds by 
prolonging the duration of action. Formulation of sustained release 
buoyant tablet dosage form was based on two level (23) factorial 
experimental design; proportion of polymer content-to-drug content 
was studied as important control variable because of its influence on 
release of GBP through the hydrophilic matrices, formed from 
hydrocolloid polymeric system made up of carbopol grades (934 
and 940) combined with SCMC which slows down the drug release. 
Throughout the experiments concentrations of matrix forming 
agents were increased; polymers absorb water, hydrogel layer forms 
around the tablet that regulates the release of drug molecules. 25% 
w/w sodium bicarbonate based gas generating system used in the 
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hydrophilic matrices produced excellent buoyancy by liberating 
carbon dioxide to prolong gastrointestinal residence for the tablets. 
Swelling index for all the batches was represented in (fig. 3).  
Important components of the buoyant layer for drug release were 
different viscosity grades and proportion of carbopol with SCMC. 
Formulation batch S1 and S5 comprising of lowest amount of 
polymers not able to hold the drug release, apparently attributed to 
poor strength and lose structure of matrix whereas formulation 
batches S2, S4, S6 and S8 exhibited 97% drug release across 12 h. 
Formulation batch S3 and S7 comprising of high amount of polymers 
shown slower release rate and dissolution over extended time 
period, refers to excellent strength and dense structure of 
hydrophilic matrix. Drug release profiles for the buoyant GBP tablet 
formulations of 23 factorial designs were expressed in (fig. 4). The 
dissolution data were processed as per Korsmeyer et al.’s model (Eq. 
5), constructed curves for log cumulative % drug release vs log of 
time, shown good linearity providing diffusion exponents 0.36 to 
0.59 (table 7). The mechanism of GBP release from different batches 



















Fig. 3: % Swelling index of GBP buoyant SR tablet formulations 
(Results are expressed as mean±SD, n=3)
 
 
Fig. 4: In vitro drug release profile of GBP buoyant SR tablet formulation (Results are expressed as mean±SD, n=6) 
 
Table 7: Curve-fitting data of release rate profile by factorial design 
Batch Y1 GBP 
release at 




Correlation coefficient values (R2) Y3 
Diffusion 
coefficient (n) 
Zero-order First-order Higuchi Korsmeyer- 
peppas 
S1 101.32 2.4 0.85 0.89 0.93 0.94 0.36 
S2 99.34 3.2 0.86 0.88 0.90 0.93 0.39 
S3 96.74 4.2 0.83 0.90 0.92 0.96 0.50 
S4 98.28 3.8 0.81 0.87 0.89 0.97 0.59 
S5 99.81 2.6 0.87 0.90 0.93 0.95 0.38 
S6 98.58 3.3 0.80 0.86 0.91 0.94 0.45 
S7 95.90 4.4 0.82 0.88 0.90 0.98 0.50 
S8 97.17 3.9 0.86 0.84 0.88 0.97 0.48 
 
Statistical analysis and optimization for GBP tablets 
The experimental results were processed through statistical analysis 
to get response variables by ‘Design-Expert’ Software (Version 7.0.0) 
[Stat-Ease Inc., Minneapolis, Minnesota (USA)]. The design was 
evaluated using factorial linear interactive first-order model (Eq. 6). 
Each expression of the coefficients within the regression model was 
abbreviated in (table 8). 
Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3  … 6
 
Table 8: Regression equations for the responses 
1 =  98.39 − 1.371 − 0.052 − 0.533 + 0.7512 + 0.0413 + 0.0623 2 = 3.48 + 0.601 + 0.0752 + 0.0753 − 0.312 + 0.0 13 − 0.02523 3 = 0.47 + 0.0751 − 0.03512 + 0.01023 4 = 15.30 + 4.111 − 0.262 + 0.583 − 0.8112 − 0.1713 + 0.03523 
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Optimization of the process was made to get reactions Y1, Y2, Y3 and 
Y4 through incepted polynomial equations. The selected formulation 
was arrived through optimizing the amount of GBP release at 12 h; 
increasing buoyancy time and T50 % to find the preferred quantities 
of total polymer-to-drug proportion (X1), the polymer-to-polymer 
proportion (X2) and polymer grade (X3). Contour plot for GBP 
release at 12 h (Y1); (fig. 5) demonstrated the relationship with 
controlled variables. Findings of the optimization process indicated 
ideal experimental setup; (2:1) proportion of total polymer content-
to-drug content and polymer-to-polymer proportion (1:1) whereas 
carbopol (934 and 940) polymer viscosity grades did not 
significantly affect the performance of the tablet dosage form. 
 
 
Fig. 5: Contour plot demonstrating the influence of polymer content-to-drug proportion (X1) and polymer-to-polymer proportion (X2) on 
the percentage of GBP release at 12 h (Y1) 
 
Evaluation of bilayer tablet of TH and GBP 
Different attributes of bilayer tablets were investigated; tablet 
appears smooth flat circular in distinctive two layers and deviation 
in thickness found less than 5%. The average weight of bilayer tablet 
was found (579.20 mg) and weight variation (5%) within the limit. 
Found friability (0.55%) below 1%; drug content 90-110% within 
limit, (101.8±0.75 for TH and 102.4±0.58 for GBP) and 6.72 in 
kg/cm2 tablet crushing strength (hardness). 
Dissolution study 
In vitro drug release study for bilayer tablet, TH layer was indicated 
93.14 % drug release within 15 min whereas GBP layer exhibited 
slow sustained drug release, during 12h dissolution study 94.87% 
drug was released. In vitro drug release profile was constructed for 
tramadol (fig. 6) and gabapentin (fig. 7). 
 
 
Fig. 6: In vitro drug release profile of Tramadol IR layer (Results 
are expressed as mean±SD, n=6) 
 
Fig. 7: In vitro drug release profile of gabapentin buoyant SR 
layer (Results are expressed as mean±SD, n=6) 
 
CONCLUSION 
Chronic neuropathic pain is a disease, not a symptom and combination 
pharmacotherapy is often necessary. Neuropathic pain significantly 
affects day to day life of an individual, needs to be managed with 
multiple approaches. Available medication options together with 
modern dosage form technology can provide the excellent therapeutic 
result to overcome the painful condition and improve the quality of life 
for an individual suffering from neuropathic pain. Developed bilayer 
buoyant tablet will provide immediate pain relief by releasing TH within 
30 min and suppressing burning-fire pain stimulation of nerves for a 
longer duration through sustained release of GBP with once a day 
administration of bilayer tablet. 
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